SCHEMBL2009235

SCHEMBL2009235

Cc1ccc(-c2ccc(S(=O)(=O)OCCCCC(N)=O)cc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.47
PSMD10 O75832 1/20 0.42
KMT2A Q03164 2/20 0.42
RAB9A P51151 1/20 0.42
STAT3 P40763 2/20 0.42
LMNA P02545 1/20 0.41
HPGD P15428 1/20 0.41
HTT P42858 1/20 0.41
POLB P06746 1/20 0.40
PKM P14618 1/20 0.39
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA9 Q16790 1/20 0.38
F2 P00734 2/20 0.38
PRSS1 P07477 2/20 0.38
PRSS2 P07478 2/20 0.38
PRSS3 P35030 2/20 0.38
KIF11 P52732 1/20 0.38
MAPT P10636 1/20 0.38
CYP3A4 P08684 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9709447 0.95 ALDH1A1 (0.51) ALDH1A1PSMD10KMT2ARAB9ASTAT3
SCHEMBL2013462 0.87 LMNA (0.42) KMT2ALMNACA12CA1CA9
SCHEMBL2004234 0.87 MMP2 (0.50) CA12CA1CA9LTB4R
SCHEMBL11217755 0.86 ALDH1A1 (0.45) ALDH1A1PSMD10KMT2ARAB9ASTAT3
SCHEMBL2012396 0.86 MEN1 (0.50) ALDH1A1PSMD10KMT2ARAB9ALMNA
SCHEMBL2008430 0.85 MEP1B (0.40) LMNAF2PRSS1PRSS2PRSS3
SCHEMBL28974745 0.85 ALDH1A1 (0.44) ALDH1A1PSMD10KMT2ARAB9ASTAT3
SCHEMBL19386611 0.85 ALDH1A1 (0.44) ALDH1A1PSMD10KMT2ARAB9ASTAT3
SCHEMBL6238329 0.85 STAT3 (0.47) ALDH1A1PSMD10KMT2ARAB9ASTAT3
SCHEMBL2009137 0.85 HDAC1 (0.42) KMT2ARAB9APOLBCA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7964643-B2 Biphenyl-4-sulfonic acid-(4-hydroxybutyl)-amide and derivatives; inhibits osteoclast survival, formation, and/or activity and/or inhibits bone resorption; osteoporosis, rheumatoid arthritis, cancer associated bone disease, Paget's disease, antiinflammatory, -carcinogenic agents; immunostimulants THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) 2011-06-21 US disclosed
EP-1756046-B1 ARYL ALKYL SULFONAMIDES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS UNIV ABERDEEN (GB) 2009-12-09 EP disclosed
US-20080119555-A1 Aryl Alkyl Sulfonamides As Therapeutic Agents For The Treatment Of Bone Conditions THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) 2008-05-22 US disclosed
EP-1756046-A2 ARYL ALKYL SULFONAMIDES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS The University Court of The University of Aberdeen (GB) 2007-02-28 EP disclosed
WO-2005118528-A2 ARYL ALKYL SULFONAMIDES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) 2005-12-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119555-A1 Aryl Alkyl Sulfonamides As Therapeutic Agents For The Treatment Of Bone Conditions ARSA, CNKSR1, BCL9L ALDH1A1 1548/4885PSMD10 943/4885KMT2A 1344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.